Neos Therapeutics Inc buy klostergang
Start price
10.03.17
/
50%
€6.31
Target price
26.10.17
€10.10
Performance (%)
44.29%
End price
26.10.17
€9.11
Summary
This prediction ended on 26.10.17 with a price of €9.11. With a performance of 44.29% the BUY prediction by klostergang was a big success. klostergang has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Neos Therapeutics Inc | - | - | - | - |
| iShares Core DAX® | -0.530% | 2.858% | 15.472% | 17.034% |
| iShares Nasdaq 100 | -0.580% | 4.871% | 28.534% | 54.277% |
| iShares Nikkei 225® | -1.097% | -1.658% | 7.461% | 3.656% |
| iShares S&P 500 | -0.730% | 2.647% | 24.918% | 45.236% |
Comments by klostergang for this prediction
In the thread Neos Therapeutics Inc diskutieren
NEOS's stock price is going to look awfully cheap
If Adzenys and Cotempla can command just 2% of the over $9 billion ADHD stimulant market, NEOS's stock price is going to look awfully cheap.
Neos' three compounds are all focused on the much larger stimulant side of the ADHD market ledger and they are all patent protected through 2032.
The FDA decision on Neos Therapeutics Inc.’s (NEOS) NT-0201, proposed for the treatment of ADHD, is due on September 15, 2017.
NT-0201 is a liquid suspension extended release formulation of amphetamine.
Amphetamines belong to a class of drugs known as prescription stimulants that are used to treat ADHD.
If approved, NT-0201 is expected to be launched in January 2018.
(Vom Mitglied beendet)